Lingling Wang

Lingling Wang

Auto-generated profile, based on publicly available information

Lingling Wang

The Fifth Affiliated Hospital, Sun Yat-sen University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
SLShunkui Luo
Shunkui Luo
ZLZhanjin Lu
Zhanjin Lu
LWLingling Wang
Lingling Wang
YLYun Li
Yun Li
YZYingjuan Zeng
Yingjuan Zeng
HLHongyun Lu
Hongyun Lu
The experiment demonstrated that HIF-2α increased extracellular iron. In LO2 cells overexpressing HIF-2α, FFAs not only increased cellular lipid and triglyceride levels but also induced key features of ferroptosis, such as reduced GSH and GPX4 levels and increased LPO, despite the absence of cellular iron overload. These effects were reversed by lowering extracellular iron with DFO. Furthermore, DFO treatment increased β-oxidation protein expression and improved lipid deposition in hepatocytes, potentially through the PI3K/AKT pathway.

15 June 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
QCQijian Chen
Qijian Chen
LWLingling Wang
Lingling Wang
CLChang Li
Chang Li
WHWeihua Hu
Weihua Hu
YFYameng Fan
Yameng Fan
HLHongyun Lu
Hongyun Lu
Background: Although chronic cardio‐metabolic disease is a common comorbidity among patients with COVID‐19, its effects on the clinical characteristics and outcome are not well known. Methods and Results: This study aimed to explore the association between underlying cardio‐metabolic disease and mortality with COVID‐19 among hospitalized patients. This multicenter, retrospective, and real‐world study was conducted from January 22, 2020 to March 25, 2020 in China. Data between patients with and without 5 main cardio‐metabolic diseases including hypertension, diabetes mellitus, coronary heart disease, cerebrovascular disease, and hyperlipidemia were compared. A total of 1303 hospitalized patients were included in the final analysis. Of them, 520 patients (39.9%) had cardio‐metabolic disease. Compared with patients without cardio‐metabolic disease, more patients with cardio‐metabolic disease had COVID‐related complications including acute respiratory distress syndrome (9.81% versus 3.32%; P <0.001), acute kidney injury (4.23% versus 1.40%; P= 0.001), secondary infection (13.9% versus 9.8%; P= 0.026), hypoproteinemia (12.1% versus 5.75%; P <0.001), and coagulopathy (19.4% versus 10.3%; P <0.001), had higher incidences of the severe type of COVID‐19 (32.9% versus 16.7%; P <0.001), more were admitted to the intensive care unit (11.7% versus 7.92%; P= 0.021), and required mechanical ventilation (9.8% versus 4.3%; P 2, the mortality was 4.2%, 11.1%, and 19.8%, respectively. The multivariable‐adjusted hazard ratio of mortality among patients with cardio‐metabolic disease was 1.80 (95% CI, 1.17–2.77). Conclusions: Cardio‐metabolic disease was a common condition among hospitalized patients with COVID‐19, and it was associated with higher risks of in‐hospital mortality.